Related Experiment Video
Updated: Mar 30, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Overview: A New Era of Cancer Genomics in Lymphoid Malignancies
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Abstract:
Novel technologies including next-generation sequencing have not only delineated the molecular pathogenesis of lymphoid malignancies but also identified novel biomarkers predicting the outcome of specific therapies. In addition, many actionable genetic alterations, which can be targeted by either specific therapeutic compounds or monoclonal antibodies, have been discovered. An appropriate selection of the patients enrolled in clinical trials using novel drugs targeting specific mutations will usher in a new era of personalized medicine in clinical practice of lymphoid malignancies.
Insights
Next-generation sequencing advances lymphoid malignancy understanding, identifying biomarkers and actionable genetic targets. Patient selection for targeted therapies will drive personalized medicine in treating these cancers.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Lymphoid malignancies are complex cancers with diverse molecular underpinnings.
- Understanding these molecular details is crucial for developing effective treatments.
Purpose of the Study:
- To highlight how novel technologies like next-generation sequencing (NGS) advance the understanding of lymphoid malignancies.
- To emphasize the identification of novel biomarkers and actionable genetic alterations for targeted therapies.
Main Methods:
- Utilized next-generation sequencing (NGS) to delineate molecular pathogenesis.
- Analyzed data to identify predictive biomarkers and actionable genetic alterations.
Main Results:
- NGS has elucidated the molecular basis of lymphoid cancers.
- Identified novel biomarkers for predicting therapy outcomes.
- Discovered actionable genetic alterations targetable by specific drugs or antibodies.
Conclusions:
- Targeted therapies based on identified genetic alterations offer new treatment avenues.
- Personalized medicine approaches, guided by patient selection for clinical trials, are emerging for lymphoid malignancies.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:18Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...